Image Source: iQoncept,Shutterstock
- Blue-chip stocks provide low risk return options to investors.
- These are generally seen to pip the benchmark index in terms of returns.
- Here we zero in on three ASX-listed blue-chip stocks for the month of December.
Blue-chip stocks are generally considered by investors as a safety net in their investment portfolios. These stocks belong to leading companies which have been operating for many years, have stable cash flows, and experienced management. These are generally seen to pip the benchmark index in terms of returns. Since these provide good returns with lower risks, including blue-chip stocks in portfolios is considered to be a wise move for investors.
3 ASX-listed blue-chip shares to look at in December
However, one needs to do thorough research before taking any exposure, as sinusoidal market trends are evident.
Here are three ASX-listed blue-chip shares with over 5% year-to-date (YTD) returns, which can be looked at by investors in December.
CSL Ltd (ASX:CSL)
CSL is engaged in the development, research, manufacturing and marketing of cell culture media, human plasma fractions and pharmaceutical and diagnostic products. The biotechnology company comprises the CSL Behring business and the Seqirus business. CSL was in the new this week after Seqirus announced that the US Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of Audenz.
According to experts, the company is expected to perform on a decent note in the long term on account of strong demand for its immunoglobulins and lucrative research and development pipeline. The stock has given a YTD return of nearly 6%. In the past one year, the stock has risen by 1.4%.
Goodman Group (ASX:GMG)
Goodman Group is into business space property and international industrial, development and funds management business. The real estate firm has grown at a robust rate in the recent past on account of its strategy of developing high quality industrial properties near large urban populations.
The company’s stock price hit a new all-time high last week after it was found be the third best performing Australian REIT for financial year 2021 by global accounting and professional services firm BDO. Goodman Group’s share price has increased nearly 29% since the start of 2021. It has also gained over 35% in the last one year.
Source: © Kiosea39 | Megapixl.com
ResMed Inc is a sleep treatment medical device manufacturing company. It produces products for improving the lives of sufferers of conditions such as sleep apnoea. Experts expect the company to do well going ahead considering a huge market with just an estimated one fifth of sufferers currently diagnosed.
In the first quarter of FY2022, the company’s revenue rose 20% over the prior corresponding period to US$904 million. The net income was up 14% to US$203.6. The stock has given a YTD return of over 34%. In the past one year, the stock has risen by over 30%.
RELATED ARTICLE: Will Omicron variant derail Australia's economic recovery?
RELATED ARTICLE: 5 ASX Companies to Watch as Lucrative Metaverse Takes Shape